Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Molecular InSight's presses on with heart imaging agent

This article was originally published in Clinica

Executive Summary

A metabolic imaging agent that could nearly halve the number of patients unnecessarily hospitalised for chest pains is due to complete phase IIb US clinical trials early next year, says the product's developer Molecular Insight Pharmaceuticals. The iodine-133 labelled agent, BMIPP - for use with nuclear imaging equipment, is currently under investigation for the detection of acute coronary ischaemic syndromes (ACS) in the acute care setting.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060581

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel